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based distal protection to balloon occlusion and aspiration during PCI of diseased saphe- 
nous vein grafts. The principle safety and efficacy data will be unblinded for presentation 
in March 2003. 
3:oo pm. 
820-5 Economic and Clinical Analysis of Elective 
Percutaneous Coronary Intervention Without On-Site 
Cardiac Surgery 
Kirsten Hall Lonq, Henry H. Ting, Erin K. MC Murky, Aaron S. Terry, Thomas H. 
Tiggelaar, Ryan J. Lennon, Kirk N. Garratt, Mandeep Singh, Charanjit S. Rihal, Douglas 
L. Wood, David Ft. Holmes, Mayo Clinic, Rochester, MN 
Background: Elective percutaneous coronary interventions (PCI) are routinely performed 
at hospitals with on-site cardiac surgery (CS). Smce 1999, elective PCI has been per- 
formed at lmmanuel St. Josephs Hospital (ISJ). a community hospital without on-site CS, 
with telemedicine support from Saint Matys Hospital (SMH). 
Methods: 215 PCI patients at ISJ were matched on clinical and lesion criteria to 430 PCI 
patients at SMH. Clinical outcomes assessed included procedural success (~20% resid- 
ual stenosis and without in-hospital death, myocardial infarction, coronary bypass sur- 
gery, or repeat PCI), and target vessel failure rates at 1 year (any death. myocardial 
infarction, or target vessel revascularization). Economic outcomes included billed 
charges for room and board, medications, supplies, laboratory, and hospital length of 
stay. 
Results: Procedural success rates were similar between groups (ISJ 99.0%; SMH 97%). 
Target vessel failure rates were also similar between groups at 1 year follow-up (ISJ 
16%; SMH 16%, P=O.80). Results of the economic comparison are shown in the table. 
Patients undergoing PCI at ISJ had significantly higher charges for medication and sup- 
plies reflecting higher utilization of stents (93% versus 86%) and glycoprotein Ilb/llla 
inhibitors (88% versus 57%). 
Conclusions: Favorable clinical outcomes can be achieved at a hospital without on-site 
CS at additional cost. Economic analyses are ongoing lo assess the relative cost-effec- 
tiveness of providing PCI without on-site CS. 
Economic Endpoints (2000 Constant Dollars) 
ISJ SMH Bootstrapped 95% Cl (mean P-value 
(mean) (mean) difference) 
Room and $2422 $2341 (-183, 346) 0.64 
Board 
Medications $2602 $1147 (1299, 1610) <o.ooo 
1 
Laboratory $1731 $1401 (164, 486) 0.0009 
Supplies 55013 53861 (698, 1564) 0.0001 
Length of Stay 2.34 days 2.23 days (-0.173, 0.378) 0.49 
3:15 p.m. 
820-6 Genetic Risk Diagnosis System for Restenosis After 
Percutaneous Coronary Intervention 
Hideo Izawa, Yoshiji Yamada, Hideki Horibe, Tomoko Kate, Sahoko Ichihara, Fumimaro 
Takatsu. Tovoaki Murohara. Mitsuhiro Yokota. Naaova Universitv Graduate School of 
Medicine, Nagoya, Japan, &if” International lnsti& of Biotechnology, Mitake, Japan 
Background: Although genetic epidemiological studies have suggested that several 
genetic variants increase the risk for restenosis after percutaneous coronary intervention 
(PCI), the genes that contribute to this condition remain to be identified definitively. Our 
aim was to develop a reliable system for genetic risk diagnosis of restenosis after either 
plain old balloon angioplasty (POBA) or stent implantation separately. 
Methods: Restenosis was evaluated for 1390 (910 in men, 480 in women) and 1001 
(710 in men, 291 in women) coronary lesions 6 months after successful POBA or stent 
implantation, respectively. The genotypes for 19 or 18 single nucleotide polymorphisms 
(SNPs). which we previously identified in an association study of 112 polymorphisms in 
71 genes with 445 patients with myocardial infarction and 464 controls, were determlned 
in men and women. respectively, with a fluorescence- or calorimetry-based allele-spe- 
cific DNA primer-probe assay system. 
Results: Multivariate logistic regression analysis with adjustment for age, body mass 
index, and the prevalence of smoking, hypertension, diabetes mellitus, hypercholester- 
olemia, and hyperuricemia revealed that six and five SNPs were associated with resteno- 
sis after POBA or stent implantation, respectively, both in men and in women. Combined 
genotype analysis yielded maximal odds ratios of 15.09 and 44.54 for restenosis after 
POBA and of 6.64 and 117.83 for in-stent restenosis in men and women, respectively. 
Conclusions: Ten and seven genes are susceptibility loci for restenosis after PCI in Jap- 
anese men and women, respectively, and the corresponding combined genotypes may 
prove reliable for determination of genetic risk for restenosis after POBA or stent implan- 
tation. This genetic risk diagnosis system is thus expected to contribute to the prediction 
of restenosis after PCI. 
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823-1 Improvement in Symptoms and Exercise Capacity at 
Eight Weeks in a Controlled Study of Autologous Bone 
Marrow Cell Transplant in Humans With Severe 
lschemic Heart Failure 
Emerson C. Perin, Hans F. Dohmann, Radovan Borojevic, Andre Luiz S. Sousa, Hans J. 
Dohmann. Antonio C. Carvalho. Yono J. Gena. Guilherme V. Silva. Fernando Ranael. 
Suzana A: Silva, Roberto Espo&atteT James ?. Willerson, Texas Heart Institute, _ 
Houston, TX, Hospital ProCardiaco, Rio de Janeiro, Brazil 
Background: Relatively limited treatment options exist for pts with severe ischemis heart 
failure (HF). We evaluated the safety and efficacy of transendocardial (TE) delivery of 
bone marrow mononuclear cells (BMNC) to treat pts with severe HF. 
Methods Fourteen pts (57.2 * 10.5 yrs, 11 males) with severe LV dysfunction by echo 
(EF 27 * 8 %) and severe CAD not amenable to revascularization were included. Pts 
were evaluated by exercise stress tests before and 8 wks after the procedure. Bone mar- 
row (5Oml) was aspirated from the iliac crests and BMNCs were isolated. TE injections 
were performed using the Myo-Star catheter (NOGA, Biosense) to target hibernating 
myocardium in IO pts. Four pts were followed without cell implants as a control group. 
Results: Events: There were no major in-hospital events. Minor events included tram 
sient hypotension with pulmonary congestion (n=l) and PVCs (n=l) on day 1. CK-MB 
levels did not increase in 24h. Late events in the BMSC group included 1 pt that had 
NSTMI at 7 days. In the Control group 1 pt died at 8 wks. Non-invasive F/U: In tie 
BMNC group NYHA functional class decreased from 2.2+0.8 to 1.2i0.4 compared to an 
increase 2.3+ to 2.5* in the control group (p<O.O004). Exercise times increased from 
7.45 * 1.97 to 9.002 0.2 min.in the treatment group vs. 7.42+0.48 to 4.26e2.00 in the 
control group. SPECT results will be presented. 
Conclusion: Preliminary results suggest that TE delivery of BMNCs is safe and feasible. 
In this high risk and small group of pts we have observed symptomatic benefit and 
improvement in treadmill exercise time. Further studies and follow-up are needed. 
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823-2 Glycoproteln llla PIA Polymorphism and Early Outcome 
After Coronary Stenting in Patients With Adjunctive 
Abciximab Therapy 
Nicolas van Beckerath, Olga Gorchakova, Werner Koch, Julinda Mehilli, Petra 
Hoppmann, Adnan Kastrati, Albert Schomig, TV Mtinchen, Munich, Germany 
Background: d polymorphism of glycoprotein (GP) llla has been intensively investi- 
gated. We and others have reported that homozygous PI A2 carriage is associated with an 
increased risk of early thrombotic events following coronary artery stenting. In those 
studies only few or no patients had received abciximab. One purpose of this study was to 
test if the prothrombotic influence of the PI A2 allele afler coronary stenting persists in the 
presence of potent antiplatelet therapy with abciximab. The second purpose was to test 
whether PI A2 polymorphism that underlies most cases of alloimmunethrombocytopenia 
occurring in Caucasians is associated with thrombocytopenia in response to abciximab. 
Methods: Consecutive patients (n=2265) undergoing coronary stent implantation with 
adjunctive abciximab therapy were included in the study. Serial platelet counts were 
obtained (baseline, 6. 16. 24, 72h post intervention and before discharge) and in case of 
a platelet count -c 100 OOO/fl pseudothrombocytopenia was excluded or confirmed. GP 
llla PIA genotyping was performed with a TaqMan assay. Thrombotic events (death, 
myocardial infarction and stent thrombosis) were recorded during the first 30 days follow- 
ing stent implantation. Acute profound thrombocytopenia was defined as a true drop in 
platelet count to < 20 OOOifl within 24h. 
Results: The overall genotype distribution was 2.8% PlA*‘A2. 26.7% PiAziA’ and 70.5% 
Fi”““‘, Early thrombotic events were observed in 4.8% of PIAZ’*‘, 5.0% of PlA2IA’ and 
5.4% of PIA”A’ patients (P=O.EE). Acute profound thrombocytopenia developed in 14 
patients (I PlA2’A2. 7 FlA21A’ and 6 PIA’“‘). Thus, carrying PlA2was afflicted with a three- 
fold increase of the risk to develop acute profound thrombocytopenia (OR 3.2 [95% Cl, 
1 1 I-9.301). 
Conclusions: Adjunctive abciximab therapy appears to eliminate the previously 
described prothrombotic influence of the PI w allele in the setting of coronary stenting. 
Plm carriers, though, have an increased risk lo develop acute profound thrombocylope- 
nia in response to this therapy. 
